Millennium Management LLC cut its holdings in Uniqure NV (NASDAQ:QURE) by 12.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 666,171 shares of the biotechnology company’s stock after selling 93,414 shares during the period. Millennium Management LLC’s holdings in Uniqure were worth $25,181,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of the business. Redmile Group LLC acquired a new position in Uniqure in the 2nd quarter valued at $61,402,000. Macquarie Group Ltd. increased its holdings in shares of Uniqure by 1.5% during the 2nd quarter. Macquarie Group Ltd. now owns 598,900 shares of the biotechnology company’s stock worth $22,639,000 after buying an additional 8,900 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Uniqure during the 2nd quarter worth $937,000. Baker BROS. Advisors LP increased its holdings in shares of Uniqure by 21.0% during the 2nd quarter. Baker BROS. Advisors LP now owns 605,000 shares of the biotechnology company’s stock worth $22,869,000 after buying an additional 105,000 shares during the last quarter. Finally, RTW Investments LP increased its holdings in shares of Uniqure by 0.7% during the 2nd quarter. RTW Investments LP now owns 409,370 shares of the biotechnology company’s stock worth $15,474,000 after buying an additional 2,703 shares during the last quarter. Institutional investors own 59.32% of the company’s stock.
Shares of Uniqure stock opened at $39.64 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.36 and a quick ratio of 8.36. Uniqure NV has a twelve month low of $8.66 and a twelve month high of $43.23. The firm has a market cap of $1.43 billion, a P/E ratio of -13.48 and a beta of 0.22.
A number of research firms have recently commented on QURE. HC Wainwright upped their price objective on Uniqure from $42.00 to $48.00 and gave the stock a “buy” rating in a report on Monday. Zacks Investment Research upgraded Uniqure from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a report on Wednesday, July 4th. Cantor Fitzgerald set a $58.00 price objective on Uniqure and gave the stock a “buy” rating in a report on Thursday, August 23rd. Cowen restated a “buy” rating on shares of Uniqure in a report on Monday, August 13th. Finally, B. Riley began coverage on Uniqure in a report on Wednesday, June 27th. They set a “buy” rating and a $50.00 price objective for the company. Two research analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $45.56.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
Recommended Story: What is the Ex-Dividend Date in Investing?
Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Uniqure NV (NASDAQ:QURE).
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.